Mivacurium Kalceks (Mivacurium)

Mivacurium is a short‑acting non‑depolarizing neuromuscular blocker used in procedures that require rapid, temporary muscle relaxation.

• Facilitation of endotracheal intubation: provides brief, reliable paralysis to allow safe airway placement.
• Short surgical procedures: enables skeletal muscle relaxation for operations typically lasting less than 30 minutes.
• Diagnostic procedures requiring muscle relaxation: assists in bronchoscopy, endoscopy or other examinations where brief paralysis improves conditions for the clinician.

• Mivacurium competitively antagonizes nicotinic acetylcholine receptors at the neuromuscular junction, preventing acetylcholine from activating the receptor complex. This blockade inhibits depolarization of skeletal muscle end‑plates, resulting in a rapid, short‑lasting loss of muscle tone without causing depolarization of the membrane itself.

Mivacurium may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

• Transient hypotension: mild drop in blood pressure shortly after injection.
• Flushing or erythema: skin reddening at the injection site or generalized.
• Bronchospasm: narrowing of airways, especially in susceptible individuals.
• Tachycardia: temporary increase in heart rate.
• Nausea or vomiting: gastrointestinal upset following administration.
• Headache: mild to moderate headache during recovery.

Serious or Rare Side Effects

• Anaphylaxis: severe allergic reaction requiring immediate intervention.
• Prolonged apnea: unexpected extension of muscle paralysis beyond the intended period.
• Malignant hyperthermia susceptibility: rare hypermetabolic crisis in predisposed patients.
• Cardiac arrest: life‑threatening loss of cardiac function.
• Severe hypotension: marked blood pressure decline needing vasopressor support.
• Respiratory depression: inadequate ventilation after drug effect wears off.

When using Mivacurium, clinicians should observe several safety measures to minimize risk.

• Assess neuromuscular function: monitor depth of blockade with a peripheral nerve stimulator.
• Avoid in patients with known hypersensitivity to mivacurium or related compounds.
• Use with caution in hepatic or renal impairment: altered metabolism may prolong effect.
• Consider dose reduction in elderly or debilitated patients.
• Monitor cardiovascular status: watch for hypotension or arrhythmias during infusion.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Mivacurium can interact with other agents that influence neuromuscular transmission or cardiovascular stability.

Major Interactions (Avoid)

• Other neuromuscular blocking agents: additive paralysis may be profound.
• Cholinesterase inhibitors (e.g., neostigmine, pyridostigmine): can potentiate or prolong block.
• Aminoglycoside antibiotics (e.g., gentamicin, streptomycin): enhance neuromuscular blockade.
• Magnesium salts: increase sensitivity to mivacurium.
• Inhalational anesthetics (e.g., sevoflurane, desflurane): synergistic effect on muscle relaxation.

Moderate Interactions (Monitor Closely)

• CNS depressants (e.g., propofol, benzodiazepines): may deepen sedation when combined.
• Beta‑blockers: can accentuate bradycardia if hypotension occurs.
• Calcium channel blockers: may affect hemodynamic response.
• Diuretics that alter electrolyte balance: monitor for enhanced blockade.
• Antihistamines: possible additive effect on hypotension.